The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Angelini Ventures has already invested €125 million in 22 startups
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Subscribe To Our Newsletter & Stay Updated
